Andrew King

Andrew King

Company: Chinook Therapeutics

Job title: Chief Scientific Officer


Neutralization of APRIL with BION-1301: A Targeted, Potentially Disease-Modifying Approach to IgA Nephropathy 4:00 pm

Learn how excess production of galactose-deficient IgA1 (Gd-IgA1) by IgA secreting plasma cells is considered the initiating pathogenic event (Hit 1) in IgAN Hear about PRoliferation Inducing Ligand (APRIL), a TNF-family cytokine that drives IgA class-switching, survival of IgA-secreting plasma cells and stimulates Gd-IgA1 secretion Explore how BION-1301, a novel humanized monoclonal antibody that binds…Read more

day: Day Two

Panel Discussion: Challenges & Opportunities in Drug Development for Rare Kidney Diseases 4:00 pm

Precision medicine in rare kidney disease drug development Strategies in selecting endpoints for regulatory approval Partnering with patient advocacy groups and registriesRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.